Submissions

Author Guidelines

Quarterly Pakistan Journal of Kidney Diseases  (PJKD) conforms to the ICMJE Recommendations revised in 2016.

We publish materials of interest to the practitioners and scientists in the field of Nephrology, Dialysis, Hypertension and Kidney Transplantation. The manuscripts should be able to help the practitioners and scientists to their knowledge in regards to clinical practice, medical education, research and health care reforms.

Manuscript submission is via "OJS"  and is self explanatory. If you have trouble submitting the manuscript, email us at pjkdsubmissions@gmail.com or pjkdofficial@gmail.com or ntarif@yahoo.com. or use help with in the OJS for guidance.

Office Address:

Dr. Nauman Tarif

Editor & Publisher PJKD

FMH, Shadman, Lahore 54000, Pakistan

Telephone:0092(042)–111555600, Ext 347 & 39 
Timings: 9am – 3pm (Monday to Friday except public holidays)

Submission Fees:There are no submission fees currently.

General Guidelines:All articles to be submitted in MS word, images can be submitted as jpeg or pdf format.

Ethical Approval:

Ethical approval of research should accompany the submission document except for letters to the editor, review articles, and special communications in the form of a review. In institutions where Institutional review board is not functional then a letter from the institutions or unit head declaring that the study has been conducted with no ethical issues according to the Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments:humans  http://www.wma.net/en/30publications/10policies/b3/index.html; EU Directive 2010/63/EU for animal experiments  http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm

Registration of Clinical Trial:

To ensure the integrity of the reporting of patient-centered trials, authors are encouraged (not mandatory) to register prospective clinical trials (phase II to IV trials) in publicly available repositories. For example www.clinicaltrials.gov or any of the primary registries that participate in the WHO International Clinical Trials Registry Platform.

The trial registration number (TRN) and date of registration should be included as the last line of the manuscript abstract.

Submission Form by Authors: ( Download form)

Ensure that you have the following information in hand while filling out the form:

1. Details of the contributions made by each author
2. List of disclaimers if required
3. List of possible conflict of interests for disclosure
4. List of possible sources of funding.
5. Details regarding all authors including:
   1. Full names of all authors
   2. Email addresses of all authors
   3. Phone numbers of all authors
   4. Full current affiliation of all authors
   5. Year of study if any of the authors are undergraduate students

All authors must read the copyright statement and the undertaking detailed on the form before signing it. PJKD assumes that all authors comply with the editorial policy on receipt of the signed submission form.

Manuscript Order

        Title Page should include:

       1.Title should be of 150 character limit including spaces.

2. Running title (no more than 35 characters including spaces)
3. Authors (first name, middle initial and last names) and affiliations (including division and/or department),
4. Abstract
5. Corresponding author’s name, address, and e-mail information
6. Key words.

Abstract 

Introduction

Materials and Methods

Results

Discussion

Disclosures/Conflict of Interest

Acknowledgments (include funding information)

References (30 or fewer for original articles)

Tables (all cited) with appropriate descriptive titles

Figures and legends (all cited)

Abstract. Total word count <250.

The abstract should consist of four paragraphs labeled as follows:

• Background and objectives
• Materials & Methods
• Results
• Conclusions

Abstracts other than the original article will be submitted as paragraphs without heading total word count of 100-150.

 Key words:

Abstracts should be followed by 3-5 MeSH words. For assistance use: https://www.nlm.nih.gov/mesh/MBrowser.html

Introduction:

It should include the background knowledge of the research citing regional and global citations. Include the objective of the study, explaining the research question for undertaking the study without giving any conclusions of the study. total word count of upto 150 (case report 100).

Materials and Methods: Clearly describe the

Study design

Population(s)

Exposure(s) or intervention(s)

Primary outcome

Analytic methods.

Results.

 Follow these guidelines for the presentation of data within the text, tables, and figures:

1. All descriptive data for patients should be presented to the decimal place.
2. For parameter estimates (e.g., relative risks, hazard ratios, P values), use 95% confidence intervals whenever possible rather than P values.
3. Provide the actual P values.
4. P values should have only two significant decimal places, however, lower values (e.g., 0.002) are acceptable. Values smaller than 0.001 should be listed as such.
5. Pictures, illustrations should be submitted in JPEG format & manuscript in Microsoft word format.
6. Figures & Tables: 4 each are allowed for original article or review. 

Discussion.

It should include discussion of results in comparison to the local and international literature and any hypothesis generated in the research work.  limitations and major findings of the study should be discussed as appropriate.

Disclosures.

PJKD requires authors to divulge any relationships with pharmaceutical firms or other entities (e.g., employment contracts, consultancy, advisory boards, speaker bureaus etc) that could be perceived to represent a financial conflict of interest. It is the responsibility of the corresponding author to collect disclosures from every coauthor and report all conflicts to PJKD. Financial conflict of interest statements should be added to the manuscript after the conclusion section and within the submission site. If the authors have no conflicts, please state, “Disclosures: None”.

References.

List first six authors for each article cited followed by et.al. Journal names should be abbreviated according to the BIOSIS list of serials.

Vancouver style is essential for publication in PJKD. References should be cited in consecutive numerical order as first mentioned in the text and designated by the reference number in superscriptat the end of the sentence. References appearing in a table or figure should be numbered sequentially with those in text.
Acknowledgement, Conflict of interest and Funding Disclosure:
All contributors who helped in the study, may be listed in the acknowledgement section.

Disclose if the abstract has been presented or published in a conference, or published in an abstract book or any other relevant information. If the article is part of a PhD thesis, it should be disclosed.
If there are no conflict of interests, authors should still include this heading and write “none to declare.”
Figures:

Should be sent as a separate file in MS word, JPG etc with minimum dpi of 300. All figures should have a legend.

Review Process:

All articles are subject to double blind peer review and once completed will  be published as per the schedule.